Millennium Capital Advisors LLC Acquires Shares of 43,687 Pfizer Inc. $PFE

Millennium Capital Advisors LLC acquired a new stake in Pfizer Inc. (NYSE:PFE) during the 4th quarter, Holdings Channel reports. The institutional investor acquired 43,687 shares of the biopharmaceutical company’s stock, valued at approximately $1,088,000.

Other institutional investors also recently bought and sold shares of the company. Triad Wealth Partners LLC boosted its holdings in Pfizer by 1.9% in the fourth quarter. Triad Wealth Partners LLC now owns 20,466 shares of the biopharmaceutical company’s stock worth $510,000 after acquiring an additional 386 shares in the last quarter. ETF Store Inc. boosted its holdings in Pfizer by 3.8% in the fourth quarter. ETF Store Inc. now owns 10,913 shares of the biopharmaceutical company’s stock worth $272,000 after acquiring an additional 396 shares in the last quarter. Mattern Wealth Management LLC boosted its holdings in Pfizer by 4.6% in the fourth quarter. Mattern Wealth Management LLC now owns 9,161 shares of the biopharmaceutical company’s stock worth $228,000 after acquiring an additional 400 shares in the last quarter. Pines Wealth Management LLC boosted its holdings in Pfizer by 4.4% in the fourth quarter. Pines Wealth Management LLC now owns 9,430 shares of the biopharmaceutical company’s stock worth $235,000 after acquiring an additional 400 shares in the last quarter. Finally, Quest Investment Management LLC boosted its holdings in Pfizer by 1.3% in the third quarter. Quest Investment Management LLC now owns 31,768 shares of the biopharmaceutical company’s stock worth $809,000 after acquiring an additional 405 shares in the last quarter. 68.36% of the stock is owned by institutional investors and hedge funds.

Pfizer Stock Performance

Shares of PFE opened at $25.31 on Friday. The company has a current ratio of 1.25, a quick ratio of 0.94 and a debt-to-equity ratio of 0.67. The company has a market capitalization of $144.25 billion, a price-to-earnings ratio of 19.32 and a beta of 0.35. The stock has a 50 day moving average of $26.98 and a 200 day moving average of $26.19. Pfizer Inc. has a 12 month low of $22.45 and a 12 month high of $28.75.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 EPS for the quarter, beating analysts’ consensus estimates of $0.72 by $0.03. The company had revenue of $14.45 billion during the quarter, compared to the consensus estimate of $13.84 billion. Pfizer had a return on equity of 19.44% and a net margin of 11.83%.Pfizer’s revenue was up 5.4% on a year-over-year basis. During the same period last year, the business posted $0.92 earnings per share. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. As a group, sell-side analysts forecast that Pfizer Inc. will post 2.99 earnings per share for the current year.

Pfizer Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 12th. Investors of record on Friday, May 8th will be given a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.8%. The ex-dividend date of this dividend is Friday, May 8th. Pfizer’s dividend payout ratio (DPR) is presently 131.30%.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on PFE shares. Morgan Stanley increased their price target on Pfizer from $27.00 to $28.00 and gave the stock an “equal weight” rating in a report on Friday, April 10th. CICC Research started coverage on Pfizer in a report on Thursday, April 16th. They issued an “outperform” rating and a $33.00 price target on the stock. Cantor Fitzgerald reiterated a “neutral” rating and issued a $27.00 price target on shares of Pfizer in a report on Wednesday, February 4th. Argus upgraded Pfizer from a “hold” rating to a “buy” rating and set a $35.00 price target on the stock in a report on Monday, March 2nd. Finally, Zacks Research upgraded Pfizer from a “strong sell” rating to a “hold” rating in a report on Tuesday, February 24th. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, twelve have assigned a Hold rating and three have issued a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $28.84.

Key Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer announced a Europe label expansion for its hemophilia therapy Hympavzi, which could broaden the drug’s commercial opportunity and support long-term revenue growth.
• Positive Sentiment: Multiple updates highlighted ongoing clinical and development activity, including a new Korea migraine study for Nurtec ODT, a Phase 1 food-effect study for PF-07799933, a prazosin site-transfer trial, and a planned Japan RSV vaccine trial. These reinforce Pfizer’s pipeline and global expansion efforts.
• Positive Sentiment: Recent commentary around Pfizer’s Q1 earnings pointed to improving momentum in new and acquired products, especially oncology and migraine treatments, as well as progress from the Seagen integration and legal settlements that may improve clarity around future cash flow.
• Neutral Sentiment: Media coverage also noted that investor sentiment remains mixed, with some analysts and commentators arguing Pfizer still lacks strong earnings momentum and is being supported more by its dividend and defensive valuation than by a clear near-term growth catalyst.
• Negative Sentiment: Pfizer continues to face concerns about declining COVID-related sales and looming patent expirations, which have weighed on the stock even after earnings beat expectations.

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.